Vascular endothelial growth factor A (VEGF-A) heparan-sulfate binding site (VEGF-A HBD)

The heparan-sulfate binding site of Vascular Endothelial Growth Factor A (VEGF-A) is a specialized region primarily located within the heparin-binding domain (HBD) encoded by exons 6 and 7 of the VEGFA gene. This site is present in specific isoforms such as VEGF165, VEGF189, and VEGF206, but is notably absent in the freely diffusible VEGF121 isoform. The HBD allows VEGF-A to tether to heparan sulfate proteoglycans (HSPGs) in the extracellular matrix and on cell surfaces, creating a reservoir of the growth factor and establishing the spatial gradients necessary for proper vascular branching and patterning. Beyond sequestration, the heparin-binding site is essential for the recruitment of co-receptors such as Neuropilin-1 (NRP1) and certain integrins, which significantly enhance the signaling potency of VEGF-A through its primary receptor, VEGFR2. In pathological states, overactivity of heparin-binding VEGF-A isoforms drives excessive angiogenesis and vascular permeability, contributing to tumor growth and vision-threatening ocular diseases like wet age-related macular degeneration (AMD). Therapeutic targeting of this specific site, most notably by the RNA aptamer pegaptanib, offers a strategy for isoform-specific inhibition. By selectively blocking the HBD of VEGF165, these therapies can neutralize the most pathologically relevant form of VEGF-A while sparing shorter, non-heparin-binding isoforms that may have homeostatic roles. This site remains a focus for developing next-generation anti-angiogenic agents that aim to refine the balance between efficacy and systemic safety.

Other names

Heparin-binding domain of VEGF-AVEGF-A HBDVEGF165 heparin-binding siteExon 7-encoded domain of VEGF-AVascular permeability factor (VPF) heparin-binding site

Isoform-specific inhibition of VEGF-A by blocking the heparin-binding domain, preventing interaction with heparan sulfate proteoglycans and co-receptors like Neuropilin-1, thereby reducing signaling potency and bioavailability.